Cerep, Inc.

Cerep's mission focuses on "Streamlining Drug Discovery". The Company's purpose is to lower the inherent costs and uncertainty in drug discovery while simultaneously increasing speed and efficiency. Since its founding in 1989, Cerep has developed an extensive system of complementary technologies, which together form a fully integrated, operational and validated drug discovery platform. Cerep is known worldwide for its expertise in Drug Profiling, Pharmaceutical Profiling, High Throughput Organic Synthesis (HTOS), High Throughput Screening (HTS), Molecular Modeling, Virtual Screening, and Pharmaco-Informatics.

The Key Strengths of Cerep are:

1) Technological expertise in High Throughput Profiling, Virtual Screening and Pharmaco-Informatics
2) Recognized expertise in High Throughput Screening and Combinatorial Chemistry
3) High quality services in pharmacological and pharmaceutical drug characterization
4) Strong record of successful service partnerships with major pharmaceutical companies worldwide
5) Application of a highly innovative approach for chemistry library design
6) Development of a unique and powerful database for optimizing the selection of drug candidates
7) Full integration of Cerep Discovery technology platform in strategic collaborations such as those established with Sanofi-Synthelabo and Bristol-Myers Squibb

With three laboratory facilities located in France and in the USA, Cerep can create focused and lead-seeking libraries and validate lead candidates. Cerep's pharmaco-informatic approach selects qualified hits from high throughput screening and generates superior development candidates that benefit and advance from early pharmacological and PK/ADME profiling. Each phase of the Cerep Discovery platform enables rapid, continuous and rational optimization of drug candidates.